Sora Neuroscience

Sora Neuroscience operates at the intersection of neuroimaging, radiology IT, clinical research, and medical software. Its clearest market distinction is the combination of resting-state fMRI analysis with a clinically cleared product: Cirrus received FDA clearance and is intended to support neurosurgical planning. That places Sora closer to specialized imaging-software and surgical-navigation providers than to general digital-health companies. Sora’s differentiation appears to come from its multidisciplinary expertise across neuroscience, radiology, algorithm engineering, statistical analysis, product development, quality, and commercialization, supported by neurosurgical, neuroradiology, and academic advisors. The Prism Clinical Imaging distribution relationship may broaden access without requiring Sora to build an entire imaging-platform ecosystem itself. The company remains small, with an employee range of one to ten and $3.4075 million in disclosed funding across two seed rounds. That profile suggests a focused niche entrant pursuing regulated clinical adoption rather than a scaled imaging-platform competitor.

Sora Neuroscience’s trajectory shows a progression from company formation and research development toward regulated clinical software commercialization. Founded in 2020, it raised $1.98 million in a September 9, 2021 seed round, followed by $1.4275 million on October 31, 2023. The two rounds brought disclosed funding to $3.4075 million and appear to have supported continued development of functional brain-mapping technology. Patent activity recorded on July 13, 2023 focused on generating functional brain maps and related reference information, indicating an emphasis on proprietary computational methods. The major inflection point came on June 20, 2025, when Sora announced FDA clearance of Cirrus, a resting-state fMRI brain-mapping software product for neurosurgical planning. A non-exclusive distribution partnership with Prism Clinical Imaging was announced the same day, creating a channel for access through an existing brain-mapping platform. The company’s employee range remains one to ten, and no hiring acceleration, layoffs, subsequent financing, or additional product launches are documented.